Table 2.
Baseline characteristics of cases of programmed cell death-1 inhibitor-related sclerosing cholangitis
| Case | Ref. | Age | Sex | Primary disease | Drug | Cycles until onset | Symptoms |
| 1 | Gelsomino et al[21] | 79 | M | NSCLC | Nivolumab | 4 | Itching, jaundice |
| 2 | Kawakami et al[19] | 64 | M | NSCLC | Nivolumab | 9 | Fever, abdominal discomfort |
| 3 | Kawakami et al[19] | 73 | F | NSCLC | Nivolumab | 6 | Fever, vomiting, abdominal discomfort, diarrhea |
| 4 | Kawakami et al[19] | 82 | F | NSCLC | Nivolumab | 12 | Fever, general fatigue |
| 5 | Kashima et al[22] | 63 | M | NSCLC | Nivolumab | 24 | Epigastric pain, soft stool |
| 6 | Doherty et al[23] | 49 | F | Melanoma | Pembrolizumab | 1 | Jaundice |
| 7 | Doherty et al[23] | 59 | F | Melanoma | Nivolumab | 3 | None (liver dysfunction) |
| 8 | Doherty et al[23] | 76 | M | epithelioid mesothelioma | Pembrolizumab | 1 | Jaundice |
| 9 | Cho et al[24] | 69 | M | NSCLC | Avelumab | 21 | Right upper abdominal discomfort |
| 10 | Hamoir et al[25] | 71 | M | NSCLC | Nivolumab | NA (11 mo) | None (liver dysfunction) |
| 11 | Kuraoka et al[26] | 69 | M | NSCLC | Nivolumab | 3 | Pruritic rash, liver dysfunction |
| 12 | Ogawa et al[27] | 73 | M | Melanoma | Pembrolizumab | NA (3 mo) | None (liver dysfunction) |
| 13 | Kono et al[28] | 69 | F | GC | Nivolumab | 2 | Jaundice |
| 14 | Noda-Narita et al[29] | 57 | F | NSCLC | Nivolumab | NA (12 mo) | Abdominal pain |
| 15 | Sawada et al[30] | 76 | M | GC | Nivolumab | 4 | None (liver dysfunction) |
| 16 | Tallec et al[31] | 56 | F | NSCLC | Nivolumab | 16 (9 mo) | Myalgia, skin thickening |
| 17 | Oda et al[32] | 43 | M | GC | Nivolumab | 1 | Fever, tachycardia, appetite loss, malaise |
| 18 | Koya et al[33] | 66 | M | SCLC | Pembrolizumab | 5 | Epigastric pain |
| 19 | Fouchard et al[34] | 52 | M | NSCLC | Nivolumab | 8 | Abdominal pain |
| 20 | Fouchard et al[34] | NA | M | NSCLC | Durvalumab (+ tremelimumab) | 4 | Fever, abdominal pain |
| 21 | Fouchard et al[34] | 61 | M | NSCLC | Pembrolizumab | 17 | None (liver dysfunction) |
| 22 | Cǎlugǎreanu et al[35] | 43 | F | Melanoma | Nivolumab | 27 | Epigastralgia, anorexia, |
| 23 | Anderson et al[36] | 67 | M | NSCLC | Nivolumab | 8 | Right upper abdominal pain |
| 24 | Zen et al[37] | 68 | M | NSCLC | Pembrolizumab | NA (5.5 mo) | Abdominal pain, vomiting |
| 25 | Zen et al[40] | 67 | M | NSCLC | Pembrolizumab | NA (1 mo) | Fever, malaise |
| 26 | Our case | 61 | M | BC | Pembrolizumab | 5 | Fever |
| 27 | Our case | 89 | M | BC | Pembrolizumab | 4 | None (liver dysfunction) |
| 28 | Our case | 63 | M | NSCLC | Pembrolizumab | 7 | None (liver dysfunction) |
| 29 | Our case | 55 | M | NSCLC | Nivolumab | 11 | Abdominal pain |
| 30 | Our case | 81 | F | NSCLC | Nivolumab | 25 | Backache |
| 31 | Our case | 82 | F | NSCLC | Nivolumab | 2 | None (liver dysfunction) |
NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer; GC: Gastric cancer; BC: Bladder cancer; NA: Not available.